When was BioGraph 55 founded?

BioGraph 55 was founded in 2014.

Where is BioGraph 55 located?

BioGraph 55 is headquartered in San Francisco, United States.

Who is the current CEO of BioGraph 55?

Paul Tumeh of BioGraph 55. They have also founded 1 company.

Is BioGraph 55 a funded company?

BioGraph 55 is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does BioGraph 55 rank among its competitors?

BioGraph 55 ranks 1062nd amongst 1964 active competitors, of which 455 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of BioGraph 55?

BioGraph 55's top competitors include Synthego, Sutro Biopharma and Avidity Biosciences. Among them, Antheia secured the most recent funding round in January, 2026.

BioGraph 55 - 2026 Company Profile, Team, Funding & Competitors

Company Details

BioGraph 55 was established in 2014 based on discoveries in the UCLA on inhibitor immune checkpoint PD1 (Tumeh P, et al, Nature, 2014 Nov 27; 515(7528): 568–571). They have used two biomarkers, namely CD8+ T cells and T cell receptor repertoire to predict the outcome of anti-PD1 therapy in Melanoma. The company is working towards developing targeted tumor therapy by using the findings of the study. It has developed a proprietary spatial ‘omics’ platform called SPARTA to capture unique biological information that reflects a clinical disease. Additionally, the company also uses proprietary imaging analysis tools to capture clinically relevant content from the tumor microenvironment.

Website: biograph55.com
Email ID: *****@biograph55.com

Key Metrics

Founded Year

2014

Location

San Francisco, United States

Stage

Funding Raised

Investors

Pfizer Venture Investments & 1 more

Ranked

1062^nd among 1964 active competitors

Similar Companies

Synthego & 2675 more

View BioGraph 55's full profile

BioGraph 55 is a funded company. BioGraph 55 has 2 institutional investors.

View details of BioGraph 55's funding rounds and investors

The founders of BioGraph 55 is Paul Tumeh. Paul Tumeh is the CEO of BioGraph 55.

Here are the details of BioGraph 55's key team members:

Paul Tumeh: Co-Founder & CEO of BioGraph 55.
Contact Info: 1 email address

View details of BioGraph 55's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BioGraph 55 include Synthego, Sutro Biopharma and Avidity Biosciences. Here is the list of Top 10 competitors of BioGraph 55, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
2nd	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	69/100
3rd	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	RTW Investments, Takeda Ventures & 19 others	68/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Citadel, Fidelity Investments & 14 others	67/100
5th	Savara Pharma 2008, Austin (United States), Public	Developer of therapeutics for rare respiratory diseases	$67.8M	Austin Technology Incubator, Logos & 19 others	67/100
6th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
7th	Engine Biosciences 2014, Singapore (Singapore), Series A	Developer of platform technology for combinatorial genetics discovery	$86M	Polaris Partners, DHVC & 18 others	66/100
8th	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
9th	Judges Scientific 2002, London (United Kingdom), Public	Acquisition and development of scientific instrument businesses	-	Origin Capital, Lloyds Banking Group	65/100
10th	Invenra 2011, Madison (United States), Series A	Pioneering bispecific and trispecific antibody discovery and development for novel therapies	$21.3M	Venture Investors, Venture Management & 4 others	65/100
1062nd	BioGraph 55 2014, San Francisco (United States), Funding Raised	Develops drug discovery platform for immuno-oncology targets	-	Pfizer Venture Investments, Panacea Venture	26/100